# Elite Express Holding Inc.: financial statements, quarterly

ETS · Nasdaq · CIK 2053641 · [Industrials](/sectors/industrials.md) · fiscal year ends Nov 30

Pages: [Overview](/companies/ets.md) · [Financials](/companies/ets/financials.md) · [Filings](/companies/ets/filings.md) · [Insiders](/companies/ets/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ets/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-02-29) | period not labelled (2024-05-31) | period not labelled (2024-08-31) | period not labelled (2025-02-28) | period not labelled (2025-05-31) | Q3 FY2025 (2025-08-31) | Q4 FY2025 (2025-11-30) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | [590](/filings/0001104659-25-098929.md) | [692](/filings/0001104659-26-042622.md) | [630](/filings/0001104659-26-083496.md) | [634](/filings/0001104659-26-115843.md) | [710 d](/filings/0001104659-26-021557.md) | [805](/filings/0001104659-26-042622.md) | [727](/filings/0001104659-26-083496.md) | [766](/filings/0001104659-26-115843.md) |
| Cost of revenue | $k | not reported | not reported | [620](/filings/0001104659-25-098929.md) | [725](/filings/0001104659-26-042622.md) | [612](/filings/0001104659-26-083496.md) | [627](/filings/0001104659-26-115843.md) | [684 d](/filings/0001104659-26-021557.md) | [648](/filings/0001104659-26-042622.md) | [646](/filings/0001104659-26-083496.md) | [671](/filings/0001104659-26-115843.md) |
| Gross profit | $k | not reported | not reported | [(29.8)](/filings/0001104659-25-098929.md) | [(32.4)](/filings/0001104659-26-042622.md) | [18.0](/filings/0001104659-26-083496.md) | [6.8](/filings/0001104659-26-115843.md) | [25.8 d](/filings/0001104659-26-021557.md) | [157](/filings/0001104659-26-042622.md) | [81.0](/filings/0001104659-26-083496.md) | [95.8](/filings/0001104659-26-115843.md) |
| Research and development | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [2,150](/filings/0001104659-26-083496.md) | [0.0 d](/filings/0001104659-26-115843.md) |
| Operating income | $k | not reported | not reported | [(69.1)](/filings/0001104659-25-098929.md) | [(316)](/filings/0001104659-26-042622.md) | [(124)](/filings/0001104659-26-083496.md) | [(145)](/filings/0001104659-26-115843.md) | [(1,919) d](/filings/0001104659-26-021557.md) | [(307)](/filings/0001104659-26-042622.md) | [(2,775)](/filings/0001104659-26-083496.md) | [(921)](/filings/0001104659-26-115843.md) |
| Income tax | $k | not reported | not reported | [0.0](/filings/0001104659-25-098929.md) | [(106)](/filings/0001104659-26-042622.md) | [0.4](/filings/0001104659-26-083496.md) | [43.3](/filings/0001104659-26-115843.md) | [(42.5) d](/filings/0001104659-26-021557.md) | [1.6](/filings/0001104659-26-042622.md) | [0.0](/filings/0001104659-26-083496.md) | [0.0](/filings/0001104659-26-115843.md) |
| Net income | $k | [(19.3)](/filings/0001104659-25-098929.md) | [(48.7)](/filings/0001104659-25-098929.md) | [(76.5)](/filings/0001104659-25-098929.md) | [(205)](/filings/0001104659-26-115843.md) | [(108)](/filings/0001104659-26-115843.md) | [(186)](/filings/0001104659-26-115843.md) | [(1,688) d](/filings/0001104659-26-021557.md) | [(110)](/filings/0001104659-26-115843.md) | [(2,533)](/filings/0001104659-26-115843.md) | [(760)](/filings/0001104659-26-115843.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | [(0.02)](/filings/0001104659-26-042622.md) | [(0.01)](/filings/0001104659-26-083496.md) | [(0.01)](/filings/0001104659-26-115843.md) | not reported | [(0.01)](/filings/0001104659-26-042622.md) | [(0.15)](/filings/0001104659-26-083496.md) | [(0.02)](/filings/0001104659-26-115843.md) |
| Basic EPS | $ per share | not reported | not reported | not reported | [(0.02)](/filings/0001104659-26-042622.md) | [(0.01)](/filings/0001104659-26-083496.md) | [(0.01)](/filings/0001104659-26-115843.md) | not reported | [(0.01)](/filings/0001104659-26-042622.md) | [(0.15)](/filings/0001104659-26-083496.md) | [(0.02)](/filings/0001104659-26-115843.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-02-29) | period not labelled (2024-05-31) | period not labelled (2024-08-31) | period not labelled (2024-10-25) | period not labelled (2024-11-30) | period not labelled (2025-02-28) | period not labelled (2025-05-31) | Q3 FY2025 (2025-08-31) | FY2025 (2025-11-30) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | [0.2](/filings/0001104659-26-021557.md) | not reported | not reported | [13.6](/filings/0001104659-25-098929.md) | [1.3](/filings/0001104659-26-115843.md) | [0.1](/filings/0001104659-26-042622.md) | [5.2](/filings/0001104659-26-083496.md) | [3.0](/filings/0001104659-26-115843.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | [0.3](/filings/0001104659-26-021557.md) | not reported | not reported | [13.8](/filings/0001104659-25-098929.md) | [12.4](/filings/0001104659-26-115843.md) | [12.0](/filings/0001104659-26-042622.md) | [17.5](/filings/0001104659-26-083496.md) | [16.9](/filings/0001104659-26-115843.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | [1.8](/filings/0001104659-26-021557.md) | not reported | not reported | [15.2](/filings/0001104659-25-098929.md) | [13.7](/filings/0001104659-26-115843.md) | [13.4](/filings/0001104659-26-042622.md) | [18.8](/filings/0001104659-26-083496.md) | [18.2](/filings/0001104659-26-115843.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | [0.3](/filings/0001104659-26-021557.md) | not reported | not reported | [0.3](/filings/0001104659-25-098929.md) | [0.5](/filings/0001104659-26-115843.md) | [0.3](/filings/0001104659-26-042622.md) | [0.2](/filings/0001104659-26-083496.md) | [0.4](/filings/0001104659-26-115843.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | [0.5](/filings/0001104659-26-021557.md) | not reported | not reported | [0.3](/filings/0001104659-25-098929.md) | [0.5](/filings/0001104659-26-115843.md) | [0.3](/filings/0001104659-26-042622.md) | [0.2](/filings/0001104659-26-083496.md) | [0.4](/filings/0001104659-26-115843.md) |
| Shareholders' equity | $m | [0.0](/filings/0001104659-25-098929.md) | [(0.0)](/filings/0001104659-25-098929.md) | [(0.1)](/filings/0001104659-25-098929.md) | [(0.0)](/filings/0001104659-26-021557.md) | [1.4](/filings/0001104659-26-115843.md) | [1.5](/filings/0001104659-26-115843.md) | [1.5](/filings/0001104659-26-115843.md) | [14.9](/filings/0001104659-26-115843.md) | [13.2](/filings/0001104659-26-115843.md) | [13.1](/filings/0001104659-26-115843.md) | [18.5](/filings/0001104659-26-115843.md) | [17.8](/filings/0001104659-26-115843.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-02-28) | period not labelled (2025-05-31) | Q3 FY2025 (2025-08-31) | Q4 FY2025 (2025-11-30) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(297)](/filings/0001104659-26-042622.md) | [3.0 d](/filings/0001104659-26-083496.md) | [(346) d](/filings/0001104659-26-115843.md) | [(2,180) d](/filings/0001104659-26-021557.md) | [(1,249)](/filings/0001104659-26-042622.md) | [(3,096) d](/filings/0001104659-26-083496.md) | [(397) d](/filings/0001104659-26-115843.md) |
| Capital expenditure | $k | not reported | not reported | not reported | [6.4 d](/filings/0001104659-26-021557.md) | [6.4](/filings/0001104659-26-042622.md) | [0.0 d](/filings/0001104659-26-083496.md) | [0.0 d](/filings/0001104659-26-115843.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-02-28) | period not labelled (2025-05-31) | Q3 FY2025 (2025-08-31) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [16.9](/filings/0001104659-26-042622.md) | [12.9](/filings/0001104659-26-083496.md) | [13.3](/filings/0001104659-26-115843.md) | [16.7](/filings/0001104659-26-042622.md) | [16.7](/filings/0001104659-26-083496.md) | [47.3](/filings/0001104659-26-115843.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 48,716,672 at 2026-10-13, from the cover of the [10-Q filed 2026-10-14](/filings/0001104659-26-115843.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.